Mexidol [Emoxypine succinate]

Instructions for Mexidol [Emoxypine succinate]

English product name
Mexidol®

Release Form
50 mg/1 ml: amp r-d/v/v and v/m 5 ml 10, 15, 20, 50 or 100 pcs.
50 mg/1 ml: amp r-d/v/v and v/m 5 ml 10, 15, 20, 50 or 100 pcs.
50 mg/1 ml: amp r-d/v/v and v/m 2 ml 20, 50 or 100 pcs
50 mg/1 ml: amp r-d/v/v and v/m 5 ml 5 pcs
50 mg/1 ml: amp r-d/v/v and v/m 2 ml 10 pcs
50 mg/1 ml: amp r-d/v/v and v/m 2 ml 5 pcs.

Description

The solution for in/in and in/m injection is colorless or slightly yellowish, transparent.

1 ml
ethylmethylhydroxypyridine succinate 50 mg
Auxiliary substances: sodium metabisulphite - 0.4 mg, water d/i - up to 1 ml.

5 ml - glass ampoules (5) - contouring packages

ATC codes
N07XX Other drugs for the treatment of diseases of the nervous system

Clinical-pharmacological groups / Group affiliation
Antioxidant preparation

Active substance Mexidol
ethylmethylhydroxypyridine succinate Mexidol

Pharmaco-therapeutic group Mexidol

Antioxidant agent

Storage Conditions Mexidol
The drug should be stored in a place not accessible to children, protected from light at a temperature not higher than 25 ° C.

Best before date
The shelf life is three years. Do not apply after the expiry date indicated on the package.

Pharmacological effect Mexidol

It has antihypoxic, membrane-protective, nootropic, anticonvulsive and anxiolytic effects, increases the resistance of the body to stress. The preparation increases the resistance of the body to the effects of the main damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, disorders of cerebral circulation, intoxication by alcohol and antipsychotic drugs (neuroleptics).

Testimony Mexidol

• acute disorders of cerebral circulation;
• Traumatic brain injury, consequences of brain injuries;
• Dicyrculator encephalopathy;
• vegetative dystonia syndrome;
• mild cognitive disorders of atherosclerotic genesis;
• anxiety disorders in neurotic and neurotic conditions;
• acute myocardial infarction (from the first day) as part of complex therapy;
• primary open-angle glaucoma of various stages, as part of complex therapy;
• Withdrawal syndrome in alcoholism with the predominance of neurotic and vegetative vascular disorders;
• acute intoxication by antipsychotic agents;
• Acute abdominal pyo-inflammatory processes (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Method of use, course and dosage Mexidol

Method of use, course and dosage
The ® is administered in/m or in/v (either jet or drip). The infusion method of administration should dilute the preparation in a 0.9% solution of sodium chloride.
The Mexicdol® jet is administered slowly for five to seven minutes and is droplet at a rate of forty to sixty drops/min. The maximum daily dose shall not exceed one thousand two hundred mg.

• Nosology Mexidol (ICD codes)
• F07
• Personality and behavioural disorders caused by disease, damage or brain dysfunction
• F10.3
• Withdrawal State
• F40
• Phobic anxiety disorders (including agoraphobia, social phobias)
• F41.9
• Anxiety disorder unspecified
• F45.3
• Somatoform dysfunction of the autonomic nervous system
• F48.0
• Neurasthenia
• F48.9
• Neurotic disorder unspecified
• G45
• Transitory cerebral ischemic attacks [attacks] and related syndromes
• G92
• Toxic encephalopathy
• G93.4
• Encephalopathy unrefined
• H40.1
• Primary open-angle glaucoma
• I21
• Acute myocardial infarction
• I61
• Intracerebral hemorrhage (haemorrhagic type disorder)
• I63
• Brain infarction
• I67.2
• Cerebral atherosclerosis
• I67.4
• Hypertensive encephalopathy
• I69
• Effects of cerebrovascular disease
• K65.0
• Acute peritonitis (including abscess)
• K85
• Acute pancreatitis
• S06
• Intracranial injury
• T43.3
• Antipsychotic and neuroleptic drugs
• T90
• Effects of head injuries